SMO or PTCH-1 (Hedgehog)

From - A Hematology Oncology Wiki
Jump to: navigation, search

1 regimens on this page
1 variants on this page

Note: this is a new type of page for, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.

All lines of therapy

Vismodegib monotherapy


Study Evidence
Hainsworth et al. 2018 (MyPathway) Phase IIa

Eligibility criteria

  • SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations


Continued indefinitely


  1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed